Internal radiation plus immunotherapy before rectal cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of internal radiation therapy (brachytherapy) followed by an immunotherapy drug (nivolumab) before surgery for rectal cancer. The goal is to see if this approach can shrink the tumor more and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have rectal cancer that has not spread to distant organs (like the liver or lungs).
- The tumor must be in the lower or middle part of the rectum (within about 2 to 6 inches from the opening).
- Your MRI must show features that suggest the cancer is more likely to come back, such as spread to lymph nodes, the tumor being very close to the edge of the rectum, or invasion into blood vessels.
- You must not have had any previous treatment for this rectal cancer.
- You must be generally healthy enough to have surgery and accept the study treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a treatment plan for locally advanced rectal cancer that combines chemotherapy and radiation with an immunotherapy drug (PD-1 inhibitor) before surgery. The goal is to shrink the tumor and improve the chance of successful surgery and long-term control.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.